• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by RAPT Therapeutics Inc.

    12/23/24 8:20:29 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)*


    RAPT Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    75382E109

    (CUSIP Number)


    Peter Svennilson, c/o Column
    Group II, LP, 1 Letterman Drive, Building D, Suite DM-900
    San Francisco, CA, 94129
    (415) 865-2050

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    12/23/2024

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    The Column Group II, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    179,579.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    179,579.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    179,579.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.6 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consist of (i) 50,000 shares of Common Stock and (ii) 129,579 shares of Common Stock issuable upon the exercise of pre-funded warrants (the Pre-Funded Warrants) exercisable within 60 days of this joint statement on Schedule 13D/A (this Statement). This total excludes 1,222,429 shares of Common Stock subject to the Pre-Funded Warrants not exercisable within 60 days of this Statement due to a 4.99 percent ownership blocker. The securities are directly held by The Column Group II, LP (TCG II LP). The Column Group II GP, LP (TCG II GP) is the general partner of TCG II LP and may be deemed to have voting and investment power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the TCG II GP Managing Partners). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. Ownership percentage calculation is based upon 32,136,407 shares, which is based on (i) 34,958,253 of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024 (the Form 10-Q), minus (ii) 2,951,425 shares of Common Stock exchanged for Pre-Funded Warrants with the Issuer pursuant to the Exchange Agreement (as defined below in Item 6), plus (iii) 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by TCG II LP exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    The Column Group II GP, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    179,579.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    179,579.00
    11Aggregate amount beneficially owned by each reporting person

    179,579.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.6 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consist of (i) 50,000 shares of Common Stock held directly by TCG II LP and (ii) 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by TCG II LP exercisable within 60 days of this Statement. This total excludes 1,222,429 shares of Common Stock subject to the Pre-Funded Warrants not exercisable within 60 days of this Statement due to a 4.99 percent ownership blocker. The securities are directly held by TCG II LP. TCG II GP is the general partner of TCG II LP and may be deemed to have voting and investment power with respect to these securities. The managing partners of TCG II GP are the TCG II GP Managing Partners. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. Ownership percentage calculation is based upon 32,136,407 shares, which is based on (i) 34,958,253 of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in the Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged for Pre-Funded Warrants with the Issuer pursuant to the Exchange Agreement, plus (iii) 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by TCG II LP exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    Ponoi Capital, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    129,579.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    129,579.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    129,579.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.4 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consist of 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants exercisable within 60 days of this Statement. This total excludes 1,469,838 shares of Common Stock subject to the Pre-Funded Warrants not exercisable within 60 days of this Statement due to a 4.99 percent ownership blocker. The securities are directly held by Ponoi Capital, LP (Ponoi LP). Ponoi Management, LLC (Ponoi LLC) is the general partner of Ponoi LP and may be deemed to have voting and investment power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the Ponoi Managing Partners). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ownership percentage calculation is based upon 32,136,407 shares, which is based on (i) 34,958,253 of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in the Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged for Pre-Funded Warrants with the Issuer pursuant to the Exchange Agreement, plus (iii) 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Ponoi LP exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    Ponoi Management, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    129,579.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    129,579.00
    11Aggregate amount beneficially owned by each reporting person

    129,579.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Consist of 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Ponoi LP exercisable within 60 days of this Statement. This total excludes 1,469,838 shares of Common Stock subject to the Pre-Funded Warrants held by Ponoi LP not exercisable within 60 days of this Statement due to a 4.99 percent ownership blocker. Ponoi LLC is the general partner of Ponoi LP and may be deemed to have voting and investment power with respect to these securities. The managing partners of Ponoi LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ownership percentage calculation is based upon 32,136,407 shares, which is based on (i) 34,958,253 of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in the Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged for Pre-Funded Warrants with the Issuer pursuant to the Exchange Agreement, plus (iii) 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Ponoi LP exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    Ponoi Capital II, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    145,401.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    145,401.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    145,401.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.5 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The shares are directly held by Ponoi Capital II, LP (Ponoi II LP). Ponoi II Management, LLC (Ponoi II LLC) is the general partner of Ponoi II LP and may be deemed to have voting and investment power with respect to these shares. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ownership percentage calculation is based upon 32,006,828 shares, which is the difference of (i) 34,958,253 shares of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in its Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged with the Issuer pursuant to the Exchange Agreement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    Ponoi II Management, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    145,401.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    145,401.00
    11Aggregate amount beneficially owned by each reporting person

    145,401.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.5 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The shares are directly held by Ponoi II LP. Ponoi II LLC is the general partner of Ponoi II LP and may be deemed to have voting and investment power with respect to these shares. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ownership percentage calculation is based upon 32,006,828 shares, which is the difference of (i) 34,958,253 shares of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in its Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged with the Issuer pursuant to the Exchange Agreement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    The Column Group IV, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,236,261.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    1,236,261.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    1,236,261.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.9 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The securities are directly held by The Column Group IV, LP (TCG IV LP). The Column Group IV GP, LP (TCG IV GP) is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LP is the general partner of TCG IV LP may be deemed to have voting, investment and dispositive power with respect to these securities. David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the TGC IV Managing Partners)are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Ownership percentage calculation is based upon 32,006,828 shares, which is the difference of (i) 34,958,253 shares of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in its Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged with the Issuer pursuant to the Exchange Agreement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    The Column Group IV-A, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    42,189.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    42,189.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    42,189.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The securities are directly held by The Column Group IV-A, LP (TCG IV-A LP). TCG IV GP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The TGC IV Managing Partners are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Ownership percentage calculation is based upon 32,006,828 shares, which is the difference of (i) 34,958,253 shares of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in its Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged with the Issuer pursuant to the Exchange Agreement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    The Column Group IV GP, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,278,450.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,278,450.00
    11Aggregate amount beneficially owned by each reporting person

    1,278,450.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 1,236,261 shares are held of record by TCG IV LP and (ii) 42,189 shares held by TCG IV-A LP. TCG IV GP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The TGC IV Managing Partners are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Ownership percentage calculation is based upon 32,006,828 shares, which is the difference of (i) 34,958,253 shares of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in its Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged with the Issuer pursuant to the Exchange Agreement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    The Column Group, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    163.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    163.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    163.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The shares are directly held The Column Group LLC (TCG LLC). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ownership percentage calculation is based upon 32,006,828 shares, which is the difference of (i) 34,958,253 shares of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in its Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged with the Issuer pursuant to the Exchange Agreement.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    Peter Svennilson
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    SWEDEN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,603,593.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,603,593.00
    11Aggregate amount beneficially owned by each reporting person

    1,603,593.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Consists of (i) 50,000 shares of Common Stock held directly by TCG II LP, (ii) an aggregate of 129,579 shares of Common Stock issuable upon exercise of Pre-Funded Warrants held directly by TCG II LP and Ponoi LP, (iii) 145,401 shares held directly by Ponoi II LP, (iv) 1,236,261 shares held directly by TCG IV LP, (v) 42,189 shares held directly by TCG IV-A LP and (vi) 163 shares held directly by TCG LLC. This total excludes an aggregate of 2,821,846 shares of Common Stock subject to Pre-Funded Warrants held by TCG II LP and Ponoi LP not exercisable within 60 days of this Statement due to a 4.99 percent ownership blocker. TCG II GP is the general partner of TCG II LP and may be deemed to have voting and investment power with respect to the shares held by TCG II LP. The managing partners of TCG II GP are the TCG II GP Managing Partners. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to the shares held by TCG II LP. Ponoi LLC is the general partner of Ponoi LP and may be deemed to have voting and investment power with respect to the shares held by Ponoi LP. Ponoi II LLC is the general partner of Ponoi II LP and may be deemed to have voting and investment power with respect to the shares held by Ponoi LP. The managing partners of each of Ponoi LLC, Ponoi II LLC and TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to the shares held by each of Ponoi LP, Ponoi II LP and TCG LLC. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The TCG IV Managing Partners are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Ownership percentage calculation is based upon 32,136,407 shares, which is based on (i) 34,958,253 of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in the Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged for Pre-Funded Warrants with the Issuer pursuant to the Exchange Agreement, plus (iii) an aggregate of 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held directly by TCG II LP and Ponoi LP.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    David V. Goeddel
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,603,593.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,603,593.00
    11Aggregate amount beneficially owned by each reporting person

    1,603,593.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Consists of (i) 50,000 shares of Common Stock held directly by TCG II LP, (ii) an aggregate of 129,579 shares of Common Stock issuable upon exercise of Pre-Funded Warrants held directly by TCG II LP and Ponoi LP, (iii) 145,401 shares held directly by Ponoi II LP, (iv) 1,236,261 shares held directly by TCG IV LP, (v) 42,189 shares held directly by TCG IV-A LP and (vi) 163 shares held directly by TCG LLC. This total excludes an aggregate of 2,821,846 shares of Common Stock subject to Pre-Funded Warrants held by TCG II LP and Ponoi LP not exercisable within 60 days of this Statement due to a 4.99 percent ownership blocker. TCG II GP is the general partner of TCG II LP and may be deemed to have voting and investment power with respect to the shares held by TCG II LP. The managing partners of TCG II GP are the TCG II GP Managing Partners. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to the shares held by TCG II LP. Ponoi LLC is the general partner of Ponoi LP and may be deemed to have voting and investment power with respect to the shares held by Ponoi LP. Ponoi II LLC is the general partner of Ponoi II LP and may be deemed to have voting and investment power with respect to the shares held by Ponoi LP. The managing partners of each of Ponoi LLC, Ponoi II LLC and TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to the shares held by each of Ponoi LP, Ponoi II LP and TCG LLC. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The TCG IV Managing Partners are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Ownership percentage calculation is based upon 32,136,407 shares, which is based on (i) 34,958,253 of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in the Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged for warrants with the Issuer pursuant to the Exchange Agreement, plus (iii) an aggregate of 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held directly by TCG II LP and Ponoi LP.


    SCHEDULE 13D

    CUSIP No.
    75382E109


    1 Name of reporting person

    Tim Kutzkey
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,553,593.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,553,593.00
    11Aggregate amount beneficially owned by each reporting person

    1,553,593.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.8 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Consists of (i) 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants exercisable within 60 days of this Statement held directly by Ponoi LP, (ii) 145,401 shares held directly by Ponoi II LP, (iii) 1,236,261 shares held directly by TCG IV LP, (iv) 42,189 shares held directly by TCG IV-A LP and (v) 163 shares held directly by TCG LLC. This total excludes 1,469,838 shares of Common Stock subject to Pre-Funded Warrants held by Ponoi LP not exercisable within 60 days of this Statement due to a 4.99 percent ownership blocker. Ponoi LLC is the general partner of Ponoi LP and may be deemed to have voting and investment power with respect to the shares held by Ponoi LP. Ponoi II LLC is the general partner of Ponoi II LP and may be deemed to have voting and investment power with respect to the shares held by Ponoi LP. The managing partners of each of Ponoi LLC, Ponoi II LLC and TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to the shares held by each of Ponoi LP, Ponoi II LP and TCG LLC. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The Ponoi Managing Partners are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Ownership percentage calculation is based upon 32,136,407 shares, which is based on (i) 34,958,253 of Common Stock outstanding as of November 7, 2024, as reported by the Issuer in the Form 10-Q, minus (ii) 2,951,425 shares of Common Stock exchanged for warrants with the Issuer pursuant to the Exchange Agreement, plus (iii) 129,579 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held directly by Ponoi LP.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value
    (b)Name of Issuer:

    RAPT Therapeutics, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    561 Eccles Avenue, South San Francisco, CALIFORNIA , 94080.
    Item 1 Comment:
    This Amendment No. 7 (Amendment No. 7) supplements and amends the Schedule 13D relating to shares of common stock, par value $0.0001 per share (the Common Stock), of RAPT Therapeutics, Inc., a Delaware corporation (the Issuer) that was filed with the Securities and Exchange Commission (the SEC) on November 8, 2019 as it was amended by Amendment No. 1 thereto filed with the SEC on February 14, 2020, Amendment No. 2 thereto filed with the SEC on August 26, 2020, Amendment No. 3 thereto filed with the SEC on October 1, 2020, Amendment No. 4 thereto filed with the SEC on August 30, 2021, Amendment No. 5 thereto filed with the SEC on September 20, 2021 and Amendment No. 6 thereto filed with the SEC on January 13, 2023 (collectively, the Amended Statement). Only those items that are reported are hereby amended; all other items reported in the Amended Statement remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Amended Statement. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.
    Item 5.Interest in Securities of the Issuer
    (a)
    See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person and Item 2 above.
    (b)
    See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person and Item 2 above.
    (c)
    Except as reported in this Statement, the Reporting Person has not effected any transactions in the Issuer's securities within the past 60 days.
    (d)
    Except as reported in this Statement, no other person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Statement.
    (e)
    On December 23, 2024, upon consummation of the Exchange (as defined below in Item 6) each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    On December 23, 2024, the Issuer entered into an exchange agreement (the Exchange Agreement) with TCG II LP and Ponoi LP, pursuant to which the TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of Common Stock, respectively, for Pre-Funded Warrants to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively, (the Exchange) in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The Exchange occurred on December 23, 2024 and the Pre-Funded Warrants were issued on December 23, 2024. Each Pre-Funded Warrant has an exercise price of $0.0001 per share. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that, immediately after giving effect to such exercise, the holder would own more than 4.99 percent of the outstanding Common Stock, which percentage may be increased or decreased at the holder's option (not to exceed 19.99 percent) upon 61 days' notice to the Issuer subject to the terms of the Pre-Funded Warrants. Separately from and subsequently to entering into the Exchange Agreement, on December 23, 2024, the Issuer entered into a Securities Purchase Agreement with certain accredited investors (the Investors), including TCG IV LP and TCG IV-A LP, pursuant to which the Issuer agreed to issue and sell to the Investors an aggregate of (i) 100,000,000 shares of Common Stock at a price per share of $0.85 and (ii) to certain Investors, in lieu of shares of Common Stock, pre-funded warrants (the Private Placement Pre-Funded Warrants) to purchase up to 76,452,000 shares of Common Stock at a price per Pre-Funded Warrant of $0.8499], for gross proceeds of approximately $150 million (the Private Placement). The material terms of the Private Placement Pre-Funded Warrants are identical to the Pre-Funded Warrants, including the beneficial ownership limitations. The Private Placement is expected to close on or about December 27, 2024. TCG IV LP and TCG IV-A LP have agreed to purchase Private Placement Pre-Funded Warrants to purchase 28,437,536 and 8970,464 shares of Common Stock, respectively, for $24,169,061.85 and $824,797.35 respectively. The descriptions of the Exchange Agreement, the Exchange, the Pre-Funded Warrant and Securities Purchase Agreement set forth herein do not purport to be complete and are subject to, and qualified in their entirety, by the full text of the Exchange Agreement, the Pre-Funded Warrant and the Securities Purchase Agreement, which are filed as exhibits to this Statement.
    Item 7.Material to be Filed as Exhibits.
     
    F. Exchange Agreement between RAPT Therapeutics, Inc. and certain holders of Common Stock, made as of December 23, 2024 G. Form of Pre-Funded Warrant (incorporated by reference herein to Exhibit 4.1 of the Issuer's Current Report on Form 8-K filed with the SEC on December 23, 2024) H. Form of Securities Purchase Agreement dated December 23, 2024 (incorporated by reference herein to Exhibit 10.2 of the Issuer's Current Report on Form 8-K filed with the SEC on December 23, 2024)

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Column Group II, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    The Column Group II GP, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    Ponoi Capital, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    Ponoi Management, LLC
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    Ponoi Capital II, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    Ponoi II Management, LLC
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    The Column Group IV, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    The Column Group IV-A, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    The Column Group IV GP, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    The Column Group, LLC
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:12/23/2024
     
    Peter Svennilson
     
    Signature:/s/ James Evangelista, Attorney-in-Fact on behalf of Peter Svennilson
    Name/Title:James Evangelista, Attorney-in-Fact on behalf of Peter Svennilson
    Date:12/23/2024
     
    David V. Goeddel
     
    Signature:/s/ James Evangelista, Attorney-in-Fact on behalf of David V. Goeddel
    Name/Title:James Evangelista, Attorney-in-Fact on behalf of David V. Goeddel
    Date:12/23/2024
     
    Tim Kutzkey
     
    Signature:/s/ James Evangelista, Attorney-in-Fact on behalf of Tim Kutzkey
    Name/Title:James Evangelista, Attorney-in-Fact on behalf of Tim Kutzkey
    Date:12/23/2024
    Get the next $RAPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RAPT

    DatePrice TargetRatingAnalyst
    1/9/2026$95.00Overweight
    Piper Sandler
    10/27/2025$70.00Buy
    Guggenheim
    10/20/2025$55.00Neutral → Overweight
    Analyst
    10/13/2025$35.00Overweight
    Barclays
    9/26/2025$37.00Market Perform → Outperform
    Leerink Partners
    7/30/2025$14.00Underweight → Neutral
    Analyst
    5/22/2025$6.00Buy
    H.C. Wainwright
    12/26/2024$10.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $RAPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on RAPT Therapeutics with a new price target

    Piper Sandler initiated coverage of RAPT Therapeutics with a rating of Overweight and set a new price target of $95.00

    1/9/26 9:07:04 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on RAPT Therapeutics with a new price target

    Guggenheim initiated coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $70.00

    10/27/25 8:48:35 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded RAPT Therapeutics from Neutral to Overweight and set a new price target of $55.00

    10/20/25 12:32:15 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Braunstein Scott was granted 4,956 shares (SEC Form 4)

    4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    2/2/26 5:58:25 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Giordano Michael F was granted 4,956 shares (SEC Form 4)

    4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    2/2/26 5:56:14 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gray Mary Ann was granted 4,956 shares (SEC Form 4)

    4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    2/2/26 5:53:34 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

    NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE:GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ:RAPT) in a transaction valued at $2.2 billion. RAPT Therapeutics was a recent, undisclosed investment within Forbion Growth Fund III's public value opportunities strategy and represents the fund's second exit. The transaction follows the acquisition of Astria Therapeutics by BioCryst for $920 million in October 2025, further underscoring the fund's strong momentum and execution capabilities.

    1/20/26 2:13:41 PM ET
    $GSK
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 44thAnnual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific Time. To access the live webcast or subsequent archived recording of the presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presen

    1/7/26 4:05:00 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

    - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W dosing - Completed $250 million public offering to strengthen balance sheet SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial re

    11/6/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by RAPT Therapeutics Inc.

    SCHEDULE 13G - RAPT Therapeutics, Inc. (0001673772) (Subject)

    2/9/26 4:53:13 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 14D9 filed by RAPT Therapeutics Inc.

    SC 14D9 - RAPT Therapeutics, Inc. (0001673772) (Subject)

    2/2/26 8:33:20 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC TO-T filed by RAPT Therapeutics Inc.

    SC TO-T - RAPT Therapeutics, Inc. (0001673772) (Subject)

    2/2/26 6:42:54 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Financials

    Live finance-specific insights

    View All

    RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

    -  RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing-  Efficacy sustained at Week 16 after a single dose of RPT904-  Well tolerated with no serious adverse events related to study drug-  Jeyou to advance RPT904 to Phase 3 development in China-  RAPT to discuss Phase 3 development path with FDA-  RAPT to host conference call at 8:30 am ET today SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologica

    10/20/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

    SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025.RAPT will host a webcast co

    10/19/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

    - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patient

    12/23/24 7:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Leadership Updates

    Live Leadership Updates

    View All

    RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibod

    6/23/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

    SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E ("IgE"), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria ("CSU").

    4/15/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

    1/6/25 8:00:00 AM ET
    $CTNM
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/14/24 1:22:39 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/14/24 9:39:56 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/12/24 4:59:18 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care